Scroll Top

WEBINAR: Key success criteria for hearing (pre)clinical trials

In collaboration with CILcare, we presented the webinar:

Key success criteria for hearing (pre)clinical trials.

During this webinar, which was hosted by Dr. Helen Blackshaw, Prof. Anne Schilder and Dr. Wahid Awad discussed the following topics:

  • Design of the preclinical studies -models, drug regimen, read out/measures- to support the clinical indication
  • Translation from preclinical to clinical with a link to
    • trial design
    • patient selection how to choose endpoints/outcome measure/diagnostics
    • access to populations: recruitment, feasibility, networks

We would like to invite you to watch the replay.

CILcare is a world’s leading R&D services company specialized in ear disorders. Based in Montpellier, Boston, and Paris, CILcare has become the one-stop partner for pharmaceutical industries, biotechs and medtechs developing novel therapies for people with hearing and otic disorders. If the importance of investigating tinnitus and hearing loss is pointed out, the underlying fundamental knowledge bases on animal models and the translational mindset are severely lacking. CILcare’s offer fills this gap by providing means to validate hypothesis towards solutions able to prevent and to reduce hearing disorders. CILcare designs and performs pharmacokinetics, efficacy, and GLP ototoxicity studies to assess drugs, medical devices, cell & gene therapies, on hearing loss, tinnitus, and otitis.

Find out more about CILcare here.